YESCARTAの薬剤に関する洞察と市場予測：2032年

YESCARTA（axicabtagene ciloleucel）は、CD19指向性の遺伝子組換え自己T細胞免疫療法です。YESCARTAでは、患者のT細胞を採取し、レトロウイルス導入により生体外で遺伝子改変を行い、CD28およびCD3-zetaコスティミュラトリードメインに結合したマウス抗CD19一本鎖可変断片（scFv）からなるキメラ抗原受容体（CAR）を発現させます。抗CD19 CAR-T細胞は、CD19を発現する標的細胞を認識して排除することができます。

YESCARTAはCD19発現がん細胞および正常B細胞に結合します。研究では、抗CD19 CAR-T細胞がCD19発現標的細胞と結合した後、CD28およびCD3-zetaコスティミュラトリードメインが下流のシグナル伝達カスケードを活性化し、T細胞の活性化、増殖、エフェクター機能の獲得、炎症性サイトカインおよびケモカインの分泌につながることが示されました。この一連の現象がCD19発現細胞の殺傷につながります。本療法は、再発または難治性のDLBCLおよび原発性縦隔大細胞性B細胞リンパ腫（PMBCL）の成人患者で、2ライン以上の全身療法後（3ライン目）の治療に適応されます。同社は、ZUMA-23をベースに1L療法におけるYESCARTAの承認申請を2025年以降に行う予定です。

当レポートでは、主要7ヶ国におけるYESCARTA市場について調査し、市場の概要とともに、2023年～2032年の売上予測データ、競合情勢、および国別動向などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 DLBCLにおけるYESCARTAの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• 規制上のマイルストーン
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済み治療法）

第4章 競合情勢（後期段階の新興治療法）

第5章 YESCARTA市場評価

• DLBCLにおけるYESCARTAの市場展望
• 主要7ヶ国分析
  • DLBCLに対する主要7ヶ国におけるYESCARTAの市場規模
• 国別市場分析
  • 米国
  • ドイツ
  • 英国

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

• 参考文献
• レポート調査手法

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: YESCARTA, Clinical Trial Description, 2023
• Table 2: YESCARTA, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: YESCARTA Market Size in the 7MM, in USD million (2019-2032)
• Table 6: YESCARTA Market Size in the US, in USD million (2019-2032)
• Table 7: YESCARTA Market Size in Germany, in USD million (2019-2032)
• Table 8: YESCARTA Market Size in France, in USD million (2019-2032)
• Table 9: YESCARTA Market Size in Italy, in USD million (2019-2032)
• Table 10: YESCARTA Market Size in Spain, in USD million (2019-2032)
• Table 11: YESCARTA Market Size in the UK, in USD million (2019-2032)
• Table 12: YESCARTA Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: YESCARTA Market Size in the 7MM, USD million (2019-2032)
• Figure 2: YESCARTA Market Size in the United States, USD million (2019-2032)
• Figure 3: YESCARTA Market Size in Germany, USD million (2019-2032)
• Figure 4: YESCARTA Market Size in France, USD million (2019-2032)
• Figure 5: YESCARTA Market Size in Italy, USD million (2019-2032)
• Figure 6: YESCARTA Market Size in Spain, USD million (2019-2032)
• Figure 7: YESCARTA Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: YESCARTA Market Size in Japan, USD million (2019-2032)

"YESCARTA Drug Insight and Market Forecast - 2032" report provides comprehensive insights about YESCARTA for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets. A detailed picture of the YESCARTA for DLBCL in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the YESCARTA for DLBCL. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the YESCARTA market forecast analysis for DLBCL in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in DLBCL.

Drug Summary:

YESCARTA (axicabtagene ciloleucel) is a CD19-directed genetically modified autologous T-cell immunotherapy. YESCARTA, a patient's T cells are harvested and genetically modified ex vivo by retroviral transduction to express a chimeric antigen receptor (CAR) comprising a murine anti-CD19 single-chain variable fragment (scFv) linked to CD28 and CD3-zeta costimulatory domains. The anti-CD19 CAR-T cells are expanded and infused back into the patient, where they can recognize and eliminate CD19-expressing target cells.

YESCARTA binds to CD19-expressing cancer cells and normal B cells. Studies demonstrated that following anti-CD19 CAR-T-cell engagement with CD19-expressing target cells, the CD28 and CD3-zeta costimulatory domains activate downstream signaling cascades that lead to T-cell activation, proliferation, acquisition of effector functions and secretion of inflammatory cytokines and chemokines. This sequence of events leads to the killing of CD19-expressing cells. The therapy is indicated to treat adult patients with relapsed or refractory DLBCL and primary mediastinal large B-cell lymphoma (PMBCL) after two or more lines of systemic therapy (third line of therapy) (National Cancer Institute, 2022). The company is planning to file the application for YESCARTA in 1L setting on the basis of ZUMA-23 in 2025 or beyond.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the YESCARTA description, mechanism of action, dosage and administration, research and development activities in Diffuse Large B-cell lymphoma (DLBCL).
• Elaborated details on YESCARTA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the YESCARTA research and development activities in DLBCL across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around YESCARTA.
• The report contains forecasted sales of YESCARTA for DLBCL till 2032.
• Comprehensive coverage of the late-stage emerging therapies for DLBCL.
• The report also features the SWOT analysis with analyst views for YESCARTA in DLBCL.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

YESCARTA Analytical Perspective by DelveInsight

In-depth YESCARTA Market Assessment

This report provides a detailed market assessment of YESCARTA for Diffuse Large B-cell lymphoma (DLBCL) in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

YESCARTA Clinical Assessment

The report provides the clinical trials information of YESCARTA for DLBCL covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Diffuse Large B-cell lymphoma (DLBCL) is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence YESCARTA dominance.
• Other emerging products for DLBCL are expected to give tough market competition to YESCARTA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of YESCARTA in DLBCL.
• Our in-depth analysis of the forecasted sales data of YESCARTA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the YESCARTA in DLBCL.

Key Questions:

• What is the product type, route of administration and mechanism of action of YESCARTA?
• What is the clinical trial status of the study related to YESCARTA in Diffuse Large B-cell lymphoma (DLBCL) and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the YESCARTA development?
• What are the key designations that have been granted to YESCARTA for DLBCL?
• What is the forecasted market scenario of YESCARTA for DLBCL?
• What are the forecasted sales of YESCARTA in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to YESCARTA for DLBCL?
• Which are the late-stage emerging therapies under development for the treatment of DLBCL?

Table of Contents

1. Report Introduction

2. YESCARTA Overview in DLBCL

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Regulatory Milestone
• 2.4. Other Developmental Activities
• 2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. YESCARTA Market Assessment

• 5.1. Market Outlook of YESCARTA in DLBCL
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of YESCARTA in the 7MM for DLBCL
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of YESCARTA in the United States for DLBCL
  • 5.3.2. Market Size of YESCARTA in Germany for DLBCL
  • 5.3.3. Market Size of YESCARTA in France for DLBCL
  • 5.3.4. Market Size of YESCARTA in Italy for DLBCL
  • 5.3.5. Market Size of YESCARTA in Spain for DLBCL
  • 5.3.6. Market Size of YESCARTA in the United Kingdom for DLBCL
  • 5.3.7. Market Size of YESCARTA in Japan for DLBCL

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options